Johnson & Johnson (JNJ)vsVale SA ADR (VALE)
JNJ
Johnson & Johnson
$239.93
+1.98%
HEALTHCARE · Cap: $567.22B
VALE
Vale SA ADR
$15.14
+1.82%
BASIC MATERIALS · Cap: $64.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Vale SA ADR generates 127% more annual revenue ($213.59B vs $94.19B). JNJ leads profitability with a 28.5% profit margin vs 6.5%. JNJ appears more attractively valued with a PEG of 1.65. JNJ earns a higher WallStSmart Score of 71/100 (B).
JNJ
Strong Buy71
out of 100
Grade: B
VALE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.5%
Fair Value
$516.67
Current Price
$239.93
$276.74 discount
Margin of Safety
-47.9%
Fair Value
$11.75
Current Price
$15.14
$3.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Keeps 28 of every $100 in revenue as profit
Strong operational efficiency at 24.0%
Earnings expanding 48.6% YoY
Generating 5.5B in free cash flow
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 27.6%
Areas to Watch
Expensive relative to growth rate
Moderate valuation
0.5% revenue growth
ROE of 5.9% — below average capital efficiency
6.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 28.5% and operating margin at 24.0%.
Bull Case : VALE
The strongest argument for VALE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : JNJ
The primary concerns for JNJ are PEG Ratio.
Bear Case : VALE
The primary concerns for VALE are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VALE is a value play — different risk/reward profiles.
VALE carries more volatility with a beta of 0.94 — expect wider price swings.
JNJ is growing revenue faster at 9.1% — sustainability is the question.
JNJ generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (71/100 vs 55/100), backed by strong 28.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Vale SA ADR
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?